Kornimate/medical-research-clean huggingface dataset:
effect of blueberries on immunity and response to flu vaccination

Conditions: Immune Response; Inflammation

Summary: this research study will test the effects of almonds on immune functions and immune response to influenza vaccine in overweight older men and postmenopausal women

a free-living parallel, single-blind, rct will be utilized. there will be two phases: phase 1 - to examine the effects of blueberries on plasma markers of immune strength, and phase 2 - to assess the response to influenza vaccine following blueberry intake. subjects will either consume their usual diet with (blueberry group) or a placebo(control group) blueberries for 8 weeks, receive the influenza vaccination, and continue the intervention for another 4 weeks. the test food will be freeze-dried powder (fdp) (\~ to 1 cup fresh blueberries) per day with the usual diet. the control will be the placebo powder with some guidelines to restrict all berries and other polyphenol-rich foods. the entire study will last 12 weeks. participants will attend a baseline clinic at which time they will be randomized to one of the two groups. clinic visits will occur at baseline, weeks 4 and 8 before, and week 4 after vaccination.

Eligibility criteria:
inclusion criteria: * older men and post-menopausal women aged 50-70 year 2. have bmi of 25-32 3. able to commute to loma linda university 3. not taking medication or supplements that affect immunity 4. agree to get vaccinated for flu exclusion criteria: 1. intolerance or allergy to blueberries 2. regular intake of blueberries and other berried (\>2 ounces/week) 3. immune system insufficiency or disease 4. using immune boosting supplements 5. exposure to antibiotics and corticoids immediately prior to study 6. uncontrolled chronic diseases and relevant psychiatric illness, including major depression 7. flu vaccination less than 10 months ago from the start of the study

Keywords: almonds immunity inflammation
reducing sedentary time in patients with heart failure

Conditions: Heart Failure

Summary: to determine the change in sedentary time and number of steps/day for older patients with heart failure at risk for mobility disability who receive a program to decrease sedentary behavior versus a standard program to increase exercise.


Eligibility criteria:
inclusion criteria: * nyha ii-iv, * age ≥ 65, * sppb score of \> 4 and ≤ 10 of 12, * and deemed (by 1° cardiologist) to be at maximal tolerated dose of heart failure medication (ace-inhibitor (ace-i)/angiotensin receptor blocker and beta blocker (bb) for patients with hf with reduced ejection fraction (hfref), and * blood pressure controlled for hf with preserved ejection fraction (hfpef) according to the american heart failure association hf guidelines. exclusion criteria: * patients requiring medication titration such as ace-i or bb, (will return to their cardiologist and be eligible after 3 months of stable medication.) * oxygen dependent lung disease, * orthopedic or neurologic disease that severely limits mobility, * active cancer diagnosis except non-melanoma skin cancer, * geriatric depression scale (gds) score of ≥ 9 , * limited life-expectancy of \<6 months, * known dementia or disease that effects ability to learn/follow directions, or * failed minicog test.

Keywords: sedentary time number of steps/day mobility disability
a prospective virtual study to evaluate the longevity of igg antibodies in individuals exposed to covid-19

Conditions: SARS-CoV-2 Acute Respiratory Disease

Summary: the primary objective of this study is to describe the longevity of igg against sars-cov-2 infection or vaccination.

this virtual clinical study will use a prospective design, to evaluate longevity and seroprevalence of igg against sars-cov-2 in approximately 800 patients as measured by dried blood spots via fingerstick using the everlywell covid-19 antibody test home collection kit. participants will be followed up to 9 months at 1, 3, 6 and 9 months after enrollment.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * willing to provide informed consent prior to participation. * cohort 1 (arm 1) - positive test results for sars-cov-2 virus by an rt-pcr or antigen test and not received any covid-19 vaccine or participated in any covid-19 vaccine trial * cohort 2 (arm 2) - received the covid-19 vaccine exclusion criteria: * unable or unwilling to provide informed consent * individuals with known conditions or treatments associated with immune impairment, such as cancer and chemotherapy
ostomy belt use associated quality of life

Conditions: Stoma Ileostomy; Stoma Colostomy

Summary: the objective of this study is to elucidate whether the use of an ostomy belt can improve the quality of life in patients with an ostomy.


Eligibility criteria:
inclusion criteria: * current patients at university of miami hospital with stoma willing to trial an ostomy belt * 18 - 70 years old * willing and able to sign informed consent exclusion criteria: * patients without stoma or unwilling to wear ostomy belt. * have any condition that, in the opinion of the investigator, would compromise the well-being of the patient or the study or prevent the patient from meeting or performing study requirements.
a randomized, open-label, two-way crossover trial to determine the pharmacokinetics of metoclopramide when administered as the orally disintegrating tablet compared to reglan® tablets in subjects with diabetic gastroparesis

Conditions: Diabetic Gastroparesis

Summary: to determine whether a new orally disintegrating tablet of reglan (metoclopramide) is metabolized faster than the conventional reglan tablet in patients with diabetic gastroparesis, pharmacokinetics following a single 10 mg dose of each formulation are being compared. subjects must be 18 or older, have type 1 or 2 diabetes with documented gastroparesis and agree to withhold medications for gastroparesis for 3 days prior to each dosing. exclusion criteria include serum glucose \>300 mg/dl, hb1ac \>10%, and concurrent illness interfering with gastrointestinal motility. subjects will stay in the clinic overnight, and pharmacokinetic sampling will continue for 8 hours after the first morning dose. the time (tmax) and amount (cmax) of peak concentration and the area under the curve (auc) from time zero to 8 hr will be compared for the 2 formulations.

see approved package insert for adverse event information.

Eligibility criteria:
inclusion criteria: * subjects must be 18 or older, have type 1 or 2 diabetes with documented gastroparesis exclusion criteria: * serum glucose \>300 mg/dl, hba1c \>10%, and concurrent illness interfering with gastrointestinal motility
a study of the safety, tolerability & immunogenicity of csl limited's influenza virus vaccine in a paediatric population

Conditions: Influenza

Summary: the purpose of this study is to determine the safety, tolerability \& immunogenicity of csl limited's influenza virus vaccine in a two dose primary vaccination series, with a 12-month booster vaccination, in a paediatric population equal to or greater than 6 months to less than 9 years old.


Eligibility criteria:
inclusion criteria: 1. be healthy male or female children, aged = or \> 6 months to \ 6 refers to 6 calendar months 2. parent(s) or guardian(s) to provide written informed consent to participate in the study; 3. be able to provide a pre-vaccination sample of up to 5ml of venous blood without undue distress/discomfort and 4. be born after a normal gestation period (between 36 and 42 weeks). exclusion criteria: 1. known allergy to eggs, chicken feathers, neomycin, polymyxin, or any components of the vaccine; 2. previous influenza vaccination; 3. clinical signs of active infection and/or an axillary temperature of = or \>37.5 degrees celsius or oral temperature of = or \>38 degrees celsius at study entry. study entry may be deferred for such individuals, at the discretion of the principal investigator; 4. confirmed or suspected immunosuppressive condition (including cancer), or a previously diagnosed (congenital or acquired) immunodeficiency disorder (including hiv); 5. current (or within the 90 days prior to receiving the study vaccine) treatment with immunosuppressive or immunomodulative medication, including systemic corticosteroids, as follows: •chronic or long term corticosteroids: \>0.5mg/kg/day of oral prednisolone or equivalent (note: use of topical or inhalant corticosteroids prior to administration of the study vaccine or throughout the study is acceptable). 6. administration of immunoglobulins and/or any blood products since birth or planned administration of such blood products during the study period; 7. participation in a clinical study or use of an investigational compound (ie a new chemical or biological entity not registered for clinical use), within the 90 days prior to receiving the study vaccine or be planning to enter such a study during the study period; 8. current treatment with cytotoxic drugs or treatment within the 6 months prior to administration of the study vaccine; 9. have a known history of guillain-barré syndrome; 10. have a major congenital defect or serious illness and 11. have a history of neurologic disorders or seizures
aromatherapy massage applied on constipation

Conditions: Constipation

Summary: aim: this study was conducted as a randomized controlled experimental study to examine the effect of abdominal massage with ginger and lavender oil on constipation in elderly individuals. design: the study was completed with 40 elderly individuals in kayseri nursing home, including 20 in intervention and 20 in control group who met the criteria for inclusion in the study. in the study, written informed volunteer consent was obtained from the individuals with the approval of the ethics committee and the permission of the institution. the elderly individuals in the intervention group underwent aromatherapy massage with ginger and lavender oils for a period of five days and 15 minutes on weekdays for four weeks according to the abdominal massage application protocol. no application was made to individuals in the control group.

aim: this study was conducted as a randomized controlled experimental study to examine the effect of abdominal massage with ginger and lavender oil on constipation in elderly individuals. design: the study was completed with 40 elderly individuals in kayseri nursing home, including 20 in intervention and 20 in control group who met the criteria for inclusion in the study. in the study, written informed volunteer consent was obtained from the individuals with the approval of the ethics committee and the permission of the institution. the data were collected by the researcher using the questionnaire form, bristol stool scale, rome iv criteria, constipation severity scale and mini mental test. the elderly individuals in the intervention group underwent aromatherapy massage with ginger and lavender oils for a period of five days and 15 minutes on weekdays for four weeks according to the abdominal massage application protocol. no application was made to individuals in the control group. the "bristol stool scale" and "constipation severity scale" were re-applied to the individuals in the intervention and control group before, during the second week of practice and at the end of practice (fourth week).

Eligibility criteria:
inclusion criteria: * elderly individuals with constipation determined by the institution doctor, * individuals diagnosed with constipation according to the roma-criteria, * individuals, who achieved a score of 24 and higher on the standardized mini mental test (smmt), * individuals, who do not have lesions disrupting skin integrity in the abdominal region, * and elderly individuals, who agreed to participate in the study were included. exclusion criteria: * individuals diagnosed with irritable bowel syndrome (ibs), * individuals who have undergone bowel surgery before, * individuals diagnosed with colon cancer, * individuals with percutaneous endoscopic gastrostomy, * individuals with umbilical hernia * and individuals allergic to lavender and ginger oil.

Keywords: nurse elderly constipation aromatherapy abdominal massage
real-time artificial intelligence assissted colonoscopy to identify and classify polyps

Conditions: Artificial Intelligence; Colonoscopy; Quality Control

Summary: to investigate the degree of the real-time detection and classification system for increasing the adenoma detection rate during colonoscopy.


Eligibility criteria:
inclusion criteria: aged 18 to 85 years old. colonoscopies for primary crc screening of the subjects are required. exclusion criteria: history of crc,inflammatory bowel disease, previous colonic resection, antithrombotic therapy precluding polyp resection.
radiographic assessment of calcific bridge formation by light activated calcium silicate versus calcium hydroxide for deep caries

Conditions: Deep Carious Lesions

Summary: sixty participants will be divided in to two groups (n=30) of patient treated by partial caries removal according to the capping material (a),where (a1)represents calcium silicate group,(a2)represent calcium hydroxide group.apply light activated calcium silicate for group (a1) in deep occlusal caries and taking the base line image after restoring the cavity with composite restoration and apply light activated calcium hydroxide for(a2)group in deep occlusal caries and taking the base line image after restoring with composite restoration.take follow up image after one year to measure the calcific bridge formation for both groups.

management of deep carious lesion may constitute a real challenge for the operator.the basic idea for treating deep caries is to enhance calcific reparative capacity.calcium hydroxide has been the gold standard as a capping material but there are some drawbacks like solubility,gaps formation and mechanical instability so a need for a capping material such as calcium silicate has shown several advantages. sixty participants will be divided in to two groups (n=30) of patient treated by partial caries removal.the first group(a1) will be treated by light activated calcium silicate and the second group(a2) will be treated by light activated calcium hydroxide after partial caries removal of deep occlusal caries then restore by composite restoration.paralleling technique using film holders and custom made bite blocks will be used to standardize the serial radiographs and to prevent the distortion of the radiographic image.an increase in dentin thickness will be measured through sequential imaging by soft ware named digora (digora optime,soredex,helsinki,finland) will be used for measurements by digitalizing the scanned image.all images will be studied carefully for an increase in dentin thickness keeping the reference point constant from the furcation area.

Eligibility criteria:
inclusion criteria: * normal adults will be recruited in this study ,all the volunteers participated in this experiment will be healthy looking free medical history. * patients have simple deep carious lesions in his /her mouth with no pain or history of sensitivity to cold which disappear immediately after removal of the stimulus. exclusion criteria: * medically compromised patients and teeth with history of spontaneous pain or tenderness to percussion were excluded from the study. * pregnant females will be excluded from the study.

Keywords: based dentin substitute dentin bridge tertiary dentin indirect pulp treatment
drug use investigation for amerge (naratriptan hydrochloride) tablet

Conditions: Migraine Disorders

Summary: the study is designed to investigate the information on safety and efficacy of naratriptan tablets on japanese subjects with migraine headache during japanese post-marketing surveillance period.


Eligibility criteria:
inclusion criteria: * subjects with migraine headache * must use naratriptan tablets for the first time exclusion criteria: * subjects with hypersensitivity to naratriptan * subjects with history, symptoms, or signs of myocardial infarction, ischemic cardiac disease, or variant angina * subjects with history of peripheral vascular disorder * subjects with history of cerebrovascular disorder or transient ischemic attacks * subjects with uncontrolled high-blood pressure * subjects with severe hepatic function disorder or renal function disorder * subjects taking ergotamine, ergotamine derivative containing product, or 5-ht1b/1d agonist
effects of mid-season camp period loading on sports injury anxiety and physical performance

Conditions: Anxiety; Exercise; Athletic Performance

Summary: the aim of this study is to investigate the effects of 3-week mid-season camp period loading on sports injury anxiety level and physical performances of professional male soccer players.

according to the periodization theory, the seasonal training process of soccer players is divided into four periods such as pre-season, early competition, late competition, and transition. in general, these periods aim to prepare soccer players for the competitive season, improve their fitness and physical performance, and reduce the risk of sports injuries. therefore, the loading applied to soccer players during these camp periods are the key determinants of physical performance enhancement and the control of sports injury risks. in particular, the mid-season camp period loading is an important requirement to maintain the gains obtained in the pre-season training programs throughout the season. in this context, sports clubs prefer regions with different physical conditions (sea level, high altitude etc.) for the camp periods and allocate serious budgets for this periods. previous studies largely focused on effects of the pre-season camp period on psychological state and physical performance in soccer players. however, few studies in the current literature focused on the mid-season camp period. to the best of authors knowledge, sports injury anxiety and physical performance responses to the mid-season camp period loading in professional soccer players has not been very well discussed. therefore the aim of this study is to investigate the effects of 3-week mid-season camp period loading on sports injury anxiety level and physical performances of professional male soccer players.

Eligibility criteria:
inclusion criteria: * volunteering to participate in study * not have any musculoskeletal disease exclusion criteria: * using any drugs or supplements * with a history of moderate to major injury within last 6 months * having any systemic disease
rectocele repair with or without internal sphincter botulinum toxin injection: a prospective randomized trial

Conditions: Obstructed Defaecation Syndrome; Anterior Rectocele

Summary: this is a single-centre, prospective randomized controlled trial on female patients with anterior rectocele associated with obstructed defecation syndrome


Eligibility criteria:
inclusion criteria: all required * female patients * symptomatic rectocele * failed conservative treatments for at least 3 months * anterior rectocele larger than 3 cm in size in defecogram. * retention of the contrast in the rectocele on defecography * obstructed defecation manifestations: excessive straining, a sense of incomplete evacuation, the need for digital manipulation during defecation, or dyspareunia exclusion criteria: * significant urinary manifestations due to anterior vaginal wall prolapse * recurrent rectocele * previous anal surgery * slow-transit constipation * faecal incontinence (fi) * abnormal thyroid functions * patients under systemic steroid treatment * patients with connective tissue disease * asa classification \>3
transition to propofol after sevoflurane anaesthesia to prevent emergence agitation

Conditions: Emergence Agitation

Summary: the aim of this randomized double-blinded study is to determine whether transition to propofol for 3 min at the end of sevoﬂurane anaesthesia reduces the incidence of ea in children undergoing genito-urinary paediatric surgeries.


Eligibility criteria:
inclusion criteria: 1. children aged 3 - 8 years 2. asa (i - ii) 3. genito-urinary surgeries: hernia, varicocele, etc. exclusion criteria: 1. patients or parental refusal 2. allergy to propofol or egg products; or a family history of malignant hyperthermia 3. operating time more than 60 minutes 4. performance of any other procedure under the same anaesthetic 5. presence of co-morbidities or congenital anomalies 6. mental disease, neurologic disease, treatment with sedatives, full stomach, or indication for rapid sequence induction.
chemotherapy combined with gene therapy in treating patients who have stage iii or stage iv breast cancer

Conditions: Breast Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. inserting the p53 gene into the tumor may increase the effectiveness of a chemotherapy drug by making tumor cells more sensitive to the drug. combining chemotherapy with gene therapy may kill more tumor cells. purpose: phase ii trial to study the effectiveness of combining chemotherapy with gene therapy in treating patients who have stage iii or stage iv breast cancer.

objectives: * determine the therapeutic efficacy of docetaxel, doxorubicin, and ad5cmv-p53 gene in patients with locally advanced breast cancer. outline: patients receive p53 gene by intralesional injection on days 1 and 2. patients also receive doxorubicin iv over 15 minutes followed 1 hour later by docetaxel iv over 1 hour on day 1. treatment repeats every 3 weeks for up to 6 courses. after completion of chemotherapy, patients with a reasonable response undergo surgical resection. projected accrual: a maximum of 60 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed breast cancer * stage iiia, iiib (excluding inflammatory breast carcinoma), or iiic or * localized stage iv * measurable disease * no metastases * hormone receptor status: * not specified patient characteristics: age * 18 and over sex * male or female menopausal status * not specified performance status * karnofsky 70-100% life expectancy * not specified hematopoietic * adequate bone marrow function hepatic * adequate liver function * hepatitis b surface antigen negative * hepatitis c antibody negative renal * adequate kidney function cardiovascular * normal cardiac function by muga and/or echocardiogram other * no psychological, familial, sociological, or geographical conditions that would preclude study * not pregnant or nursing * fertile patients must use effective barrier method of contraception prior concurrent therapy: biologic therapy * no prior gene therapy using adenoviral vectors or p53 gene product chemotherapy * no prior chemotherapy for breast cancer endocrine therapy * not specified radiotherapy * not specified surgery * not specified

Keywords: male breast cancer stage iiia breast cancer stage iiib breast cancer stage iiic breast cancer stage iv breast cancer
a randomised, cross-over, open-labelled test catheter acceptance study

Conditions: Spinal Cord Injuries

Summary: the purpose of this study is to evaluate that the test catheter is no less accepted than the speedicath (sc) catheter.

see brief summary

Eligibility criteria:
inclusion criteria: * at least 18 years of age * has normal/impaired sensation in the urethra * self-catheterises at least 4 times per day * has used clean self-intermittent catheterisation for at least 14 days * is able to open and prepare the catheters for catheterisation * has signed the informed consent before any study related-activities. exclusion criteria: * has a symptomatic urinary tract infection as assessed by the investigator * is mentally unstable as assessed by the investigator